Skip to main content
Equibles
OSRH logo

OSRH · OSR Health, Inc. · Investor Relations

Track OSRH — free

Use OSRH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OSRH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.17 +0.05 (+43.78%) At close · Aug 26
Rebalance outlook locked
Customer concentration — top 3 customers 95% of revenue

3 customers — 95% of revenue

“Three main customers of RMC have in recent years represented approximately 95% of RMC's total sales.”
View the 10-K filed Mar 31, 2026
Market Cap
$4.09M
Shares
35.12M
Volume · Aug 26 4.48M Avg daily vol (3M) 9.94M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-10-28 OSR Health Provides Shareholder Update Following Nasdaq Panel Decision
2026-08-19 OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal
2026-08-07 OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program
2026-07-31 OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment
2026-04-30 OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe
2026-04-09 OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note
2026-01-27 OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries
2026-01-14 Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones
2025-11-25 Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones

Past events

Date Event Type
2026-07-29 Woori IO - Clinical Trial Results Report: Korean University Guro Hospital Event
2026-07-02 Emerging Growth Research: Planning to Reward Long-Term Shareholders Shareholder meeting
2026-05-07 OSR Holdings Presentation at the Emerging Growth Conference, May 7, 2026 Conference
2026-05-07 Emerging Growth Research: Specialty-Financed Licensing Deal Delivers Strong De-Risking Event
2026-04-12 OSR Holdings, Inc. FY2025 Annual Report Event
2026-04-01 OSR Holdings Presentation at the Emerging Growth Conference, April 1, 2026 Conference
2026-04-01 Emerging Growth Research: 2nd Materially Positive Event in Recent Months Event
2026-03-24 Woori IO - Corporate Overview February 2026 Event
2026-02-20 Vaximm - Corporate Overview February 2026 Event
2026-02-19 Woori IO - Tech Overview Event
2025-12-10 OSR Holdings Presentation at the Emerging Growth Conference, December 10, 2025 Conference
2025-12-04 Emerging Growth Research: New Licensing Deal is a BIG Deal Event
Key facts CIK 1840425 CUSIP 68840D102 Visit website